Early acute rejection after liver transplantation (LT): Multivariate analysis of risk factors

2000 ◽  
Vol 32 ◽  
pp. 142
Author(s):  
N. Gómez-Manero ◽  
J.I. Herrero ◽  
J. Quiroga ◽  
B. Sangro ◽  
F. Pardo ◽  
...  
2005 ◽  
Vol 5 (11) ◽  
pp. 2740-2744 ◽  
Author(s):  
E. Steve Woodle ◽  
Rita R. Alloway ◽  
Joseph F. Buell ◽  
J. Wesley Alexander ◽  
Rino Munda ◽  
...  

1999 ◽  
Vol 67 (7) ◽  
pp. S214
Author(s):  
R. Reding ◽  
F. Gennari ◽  
J. Jamart ◽  
M. Janssen ◽  
E. Sokal ◽  
...  

2017 ◽  
Vol 14 (2) ◽  
pp. 173-180 ◽  
Author(s):  
Seok-Joon Jin ◽  
Sun-Key Kim ◽  
Seong-Soo Choi ◽  
Keum Nae Kang ◽  
Chang Joon Rhyu ◽  
...  

1993 ◽  
Vol 55 (4) ◽  
pp. 807-813 ◽  
Author(s):  
RUTGER J. PLOEG ◽  
ANTHONY M. DʼALESSANDRO ◽  
STUART J. KNECHTLE ◽  
MARK D. STEGALL ◽  
JOHN D. PIRSCH ◽  
...  

2015 ◽  
Vol 29 (12) ◽  
pp. 1063-1066 ◽  
Author(s):  
Mohamed A. Elfeki ◽  
Surakit Pungpapong ◽  
Petrina V. Genco ◽  
Raouf E. Nakhleh ◽  
Justin H. Nguyen ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Daniel Seehofer ◽  
Robert Öllinger ◽  
Timm Denecke ◽  
Moritz Schmelzle ◽  
Andreas Andreou ◽  
...  

Introduction. Beneath tumor grading and vascular invasion, nontumor related risk factors for HCC recurrence after liver transplantation (LT) have been postulated. Potential factors were analyzed in a large single center experience. Material and Methods. This retrospective analysis included 336 consecutive patients transplanted for HCC. The following factors were analyzed stratified for vascular invasion: immunosuppression, rejection therapy, underlying liver disease, age, gender, blood transfusions, tumor biopsy, caval replacement, waiting time, Child Pugh status, and postoperative complications. Variables with a potential prognostic impact were included in a multivariate analysis. Results. The 5- and 10-year patient survival rates were 70 and 54%. The overall 5-year recurrence rate was 48% with vascular invasion compared to 10% without (p<0.001). Univariate analysis stratified for vascular invasion revealed age over 60, pretransplant tumor biopsy, and the application of blood transfusions as significant risk factors for tumor recurrence. Blood transfusions remained the only significant risk factor in the multivariate analysis. Recurrence occurred earlier and more frequently in correlation with the number of applied transfusions. Conclusion. Tumor related risk factors are most important and can be influenced by patient selection. However, it might be helpful to consider nontumor related risk factors, identified in the present study for further optimization of the perioperative management.


2012 ◽  
Vol 44 (2) ◽  
pp. 526-528 ◽  
Author(s):  
Y.-C. Wang ◽  
T.-J. Wu ◽  
T.-H. Wu ◽  
C.-F. Lee ◽  
H.-S. Chou ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14536-e14536
Author(s):  
Tomoharu Yoshizumi ◽  
Toru Ikegami ◽  
Shohei Yoshiya ◽  
Takashi Motomura ◽  
Yohei Mano ◽  
...  

e14536 Background: There is currently no consensus on how to manage patients with hepatocellular carcinoma (HCC) while awaiting liver transplantation (LT). The guideline published in UK states that locoregional therapy should be considered for all listed patients with HCC. Living donor LT (LDLT) is a choice for treating HCC patients in organ shortage era. The aim of the present study is to clarify the risk factors of tumor recurrence after LDLT in patients who had received pre-transplant treatments (pre-Tx) for HCC. Methods: One hundred two adult patients (39 females and 63 males) who had undergone LDLT due to end-stage liver disease with recurrent HCC after pre-Tx were enrolled. The primary end-point of this study was HCC recurrence after LDLT. Recurrence-free survival rates after LDLT were calculated. Risk factors of tumor recurrence were identified using univariate and multivariate analysis. Results: The 1-, 3-, and 5-year recurrence-free survival rates were 89.4%, 80.7%, and 78.8%, respectively. Seventy-four of 102 patients underwent pre-Tx more than twice. Moreover, the times of pre-Tx, the interval between the first treatment and LDLT, and the interval between the last treatment and LDLT did not affect the outcome of LDLT. On univariate analysis, the factors affecting recurrence-free survival were exceeding the up-to-seven criteria (p<0.0001), exceeding the Kyushu University criteria (p<0.0001), neutrophil-to-lymphocyte ratio (NLR) > 4 (p=0.0001), Alpha-fetoprotein > 400 ng/ml (p<0.0001), and bilobar tumor distribution (p=0.047). A multivariate analysis identified independent risk factors for post-LDLT tumor recurrence were exceeding the up-to-seven criteria (p=0.001) and NLR > 4 (p=0.002). The 1- and 3-year recurrence-free survival rates in the recipients with exceeding the up-to-seven criteria and NLR > 4 were 30.0% and 15.0%, respectively. Conclusions: The kind or duration of pre-Tx did not affect the outcome of LDLT, but LDLT should not be performed for the patients with exceeding the up-to-seven criteria and NLR more than 4 after pre-Tx for HCC to prevent tumor recurrence.


Sign in / Sign up

Export Citation Format

Share Document